A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.
Journal Information
Full Title: CPT Pharmacometrics Syst Pharmacol
Abbreviation: CPT Pharmacometrics Syst Pharmacol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"CONFLICT OF INTEREST STATEMENT C.K. and W.H. report grants from an industry consortium (AbbVie Deutschland GmbH & Co. K.G., Astra Zeneca, Boehringer Ingelheim Pharma GmbH & Co. K.G., Grünenthal GmbH, F. Hoffmann‐La Roche Ltd, Merck KGaA, Sanofi and Novo Nordisk) for the PharMetrX program. C.K. reports grants from the Innovative Medicines Initiative‐Joint Undertaking (“DDMore”) and the Federal Ministry of Education and Research within the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), all outside the submitted work. M.J reports advisory roles (institutional): Novartis, Astra Zeneca, Basilea Pharmaceutica, Bayer, BMS, Debiopharm, MSD, Roche, Sanofi; research funding: Swiss Cancer Research; travel grants: Roche, Sanofi, Takeda. All other authors declared no competing interests for this work."
"FUNDING INFORMATION No funding was received for this work."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025